Taysha Gene Therapies Inc (NAS:TSHA)
$ 3.9199 0.4899 (14.28%) Market Cap: 733.09 Mil Enterprise Value: 578.20 Mil PE Ratio: 0 PB Ratio: 13.52 GF Score: 31/100

Q1 2023 Taysha Gene Therapies Inc Earnings Call Transcript

May 11, 2023 / 08:30PM GMT
Release Date Price: $0.709 (-5.47%)
Operator

Thank you for standing by. This is the conference operator. Welcome to the Taysha Gene Therapies First Quarter 2023 Earnings Conference Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) I would now like to turn the conference over to Hayleigh Collins, Director, Head of Corporate Communications. Please go ahead.

Hayleigh Collins

Thank you. Good afternoon, and welcome to Taysha's First Quarter 2023 Financial Results and Corporate Update Conference Call. Earlier today, Taysha issued a press release announcing financial results for the first quarter 2023. A copy of this press release is available on the company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Pasha's CEO; Sukumar Nagendran, President and Head of Research and Development; Kamran Alam, Chief Financial Officer; and Salman Bhai, Assistant Professor of Neurology at UT Southwestern. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we will be making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot